Hereditary prostate cancer and other genetic predispositions to prostate cancer

Urologia Internationalis

Volumn 60, Issue SUPPL.2, 1998, Pages 30-34

  Cussenot, O ^a,d   Valeri, A ^a   Berthon, P ^a   Fournier, G ^b   Mangin, P ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c CHU NANCY BRABOIS   (France)

^d INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

Ethnic differences; Familial aggregation; Genetic predisposition; Hereditary prostate cancer; Prostate cancer risk

Indexed keywords

ANDROGEN RECEPTOR; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ASIAN; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 1Q; CONFERENCE PAPER; ETHNIC DIFFERENCE; FAMILIAL CANCER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; MALE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CAUSALITY; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PEDIGREE; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 0031956617     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056549     Document Type: Conference Paper

References (35)

1. Pisani P, Parkin DM, Ferlay J: Estimates of the world wide mortality from eighteen major cancers in 1985 Implication for prevention and projections of future burden. Int J Cancer 1993;55:891-893.
2. Berthaut I, Mestayer C, Portais MC, Cussenot O, Mowszowicz I: Pharmacological and molecular evidence for the expression of the two steroid 5α reductase isozymes in normal and hyperplastic human prostatic cells in culture. Prostate 1997;32:155-163.
3. Ross RK, Berstem L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE: 5-alpha-reductase activity and risk of CaP among Japanese and white and black males. Lancet 1992;339:887-889.
4. Davis DL, Russel DW: Unusual length polymorphism in human steroid 5α reductase type 2 gene (SRD5A2). Hum Mol Genet 1993;2:820.
5. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK: Genetic variability of the human SRD5A2 gene: Implications for CaP risk Cancer Res 1995;55:3973-3975.
6. Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are linkage disequilibrium in men with CaP. Cancer Res 1995;55:1937-1940.
7. Manchette CL, Schwartz GG: Geographic patterns of CaP mortality. Cancer 1992.70:2861-2869.
8. Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for CaP? Anticancer Res 1990;10:1307-1312.
9. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of CaP with vitamin D receptor gene polymorphism. Cancer Res 1996.56:4108-4110.
10. Grönberg H, Damber L, Damber JE: Studies of genetic factors in CaP in twin population. J Urol 1994;152:1484-1489.
11. Mc Whorter WP, Hernandez AD, Meikle AW, Terreros JA, Smith JR, Skolnick MH, Cannon-Albright LA, Eyre HJ: A screening study of CaP in high risk families J Urol 1992;148:826-828.
12. Narod SA, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu R, Labrie F: The impact of family history on early detection of CaP. Nature Med 1995;1:99-101.
13. Aprikian AG, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, Nachabe M, Peloquin F, Déssureault J, Narod S, Begin L, Elhilali M: Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 1995;154:404-406.
14. Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, Henderson BE: Evidence of an X-linked or recessive genetic component to CaP risk. Nature Med 1995;1:827-829.
15. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC: Family history and the risk of CaP. Prostate 1990;17:337-347.
16. Tulinius H, Egilsson V, Otafsdottir H, Sigvaldason H: Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer. BMJ 1992;305:855-857.
17. Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR, West DW, Tch CZ, Stamey T: Family history of CaP risk in Blacks, White, and Asian men in the United States and Canada. Am J Epidemiol 1995;141:732-740.
18. Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwartz AG, Swanson GM, Silverman DT, Brown LM, Hoover RN, Fraumem JF: CaP risk in US blacks and whites with family history of cancer. Int J Cancer 1995;60:361-364.
19. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial CaP. Proc Natl Acad Sci USA 1992;89:3367-3371.
20. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC: Hereditary CaP: Epidemiologie and clinical features. J Urol 1993;150:797-802.
21. Valeri A, Berthon Ph, Fournier G, Buzzi JC, Briollais L, Meria P, Blanché H, Bellanné-Chantelot C, Teillac P, Demenais F, Mangin Ph, Cohen N, Le Duc A, Cussenot O: Etude PROGENE, projet français d'analyse génétique du cancer de la prostate familial: recrutement et analyse. Prog Urol 1996;6:226-235.
22. Smith JR, Freije D, Carpten JD, Grönberg H, Xu JF, Isaacs SD, et al: Major susceptibility locus for CaP on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371-1374.
23. McIndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, Li S, Gammack JT, Gay AA, Goode EL, Hood L, Ostrander EA: Linkage analysis of 49 high-risk families docs not support a common familial CaP susceptibility gene at 1q24-25. Am J Hum Genet 1997;61:347-353.
24. Latil A, Cussenot O, Fournier G, Lidereau R: Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours. Int J Cancer 1997;71:118.
25. Woolf CM: An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960;13:739-744.
26. Sun S, Narod SA, Aprikian A, Ghadirian P, Labrie F: Androgen receptor and familial CaP. Nature Med 1995;1:848-849.
27. Bishop DT, Meike AW, Slattery ML, Stringham JD, Ford MH, West DW. The effect of nutritional factors on sex hormone levels in male twins. Genet Epidemiol 1988;5:43-59.
28. Grönberg H, Damber L, Damber JE: Familial CaP in Sweden. A nationwide register cohort study. Cancer, 1996;77:138-143.
29. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV: Loss of heterozygosity of BRCA1 and other loci on chromosome 17q in human CaP. Cancer Res 1995;55:1002-1005.
30. Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V, Barkardottir RB: Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res 1995;55:4830-4832.
31. Latil A, Cussenot O, Fournier G, Lidereau R: The BRCA2 gene is not relevant to sporadic prostate tumours. Int J Cancer 1996;66:282-283.
32. Cussenot O, Valeri A, Meria P, Berthon Ph, Fournier G, Teillac P, Mangin Ph, Le Duc A: Aspects génétiques des cancers de la prostate. Pathol Biol 1996;44:737-743.
33. Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R: Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions. Cancer Res 1997;57:1058-1062.
34. Latil A, Cussenot O, Fournier G, Lidereau R: Differential chromosome allelic imbalance in the progression of human CaP. J Urol 1996;156:2079-2083.
35. Fournier G, Valeri A, Cussenot O: Formes familiales des cancers de l'appareil urogénital. Prog Urol 1996;6:343-356.